Ahmedabad, March 30, 2026: CORONA Remedies Limited (BSE: 544644, NSE: CORONA), today announced the acquisition of Wokadine® from Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), a global pharmaceutical company headquartered in Hyderabad, India.
Effective March 30, 2026, the acquisition of Wokadine®, ranked #2 in the Povidone Iodine India market[1], reinforces CORONA’s commitment to ‘Healing’ as the journey towards holistic recovery and health. This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility. This brand holds strong potential for accelerated growth under CORONA Remedies’ stewardship.
Integrating Wokadine® into its portfolio marks CORONA Remedies’ entry into the INR 648 Cr1 Povidone Iodine market.
CORONA Remedies’ sales & marketing team along with extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban and rural areas. Wokadine® comprises of 14 SKUs having different applications, helping clinicians treat the ailing community. This acquisition will be fully funded through Company’s internal accruals and cash.
Commenting on the acquisition, Mr. Tejas Kothari, Vice President – Corporate Strategy & Business Development said:
“At CORONA Remedies, we continuously assess both organic and inorganic growth opportunities, focusing on strengthening our brands by leveraging CORONA’s extensive reach, strong trust among doctors and the medical fraternity, a pan-India distribution network, and a dedicated sales and marketing team.
We believe this acquisition will enhance and strengthen our existing product portfolio. By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand.”
